Progetto di ricerca: “Multiple Myeloma (MM) witnessed the most drug approvalf for any given malignancy during the last two decades. Nevertheless, current therapies, ranging from conventional cytostatic agents such as melphalan, cyclophosphamide and steroids to novel classes of drugs, including immunomodulatory agents, proteasome inhibitors (PI), histone deacetylase inhibitors and monoclonal antibodies, can only slow disease progression, prolong survival and minimize symptoms. Bortezomib combined with dexamethasone (Vd) is considered to be one of the standards of care in the treatment of relapsed MM; the combination of venetoclax, an orally available small molecule inhibitor of BCL-2, to Vd has shown very promising efficacy and acceptable safety in this category of patients. Based on the results obtained with phase I and II studies, a randomized phase III trial has been designed to compare progression-free survival in MM patients relapsed or refractory after 1 to 3 prior therapies with either Vd vs Vd plus venetoclax”.
Titolo della ricerca: “New therapeutics options for relapsed/refractory multiple myeloma patients”